Chip maker AMD is investing $20 million in AI drug startup Absci, which will use AMD chips and software for drug development.
Strategists at HSBC led by Frank Lee lowered their price target on the shares to $110 from $200 and cut the rating to Reduce ...
Advanced Micro Devices Inc. (AMD) stock tumbled more than 3% in pre-market trading on Wednesday after HSBC analysts double ...
The $20 million deal gives the chip supplier a toehold in the life-sciences market, a strategy it plans to replicate in other ...
Absci Corporation (NASDAQ: ABSI), a data-first generative AI drug creation company, today announced a strategic collaboration with AMD to deploy AMD Instinct™ accelerators and ROCm™ software to power ...
AMD claims the Ryzen 9000 CPUs are up to 8% faster than the previous Ryzen 9 7950X3D, with improvements in games like Black ...
AMD announces its new Ryzen AI Max+ 'Strix Halo' APU with 16 cores, 32 threads of Zen 5 CPU, 40 CUs of RDNA 3.5 GPU, up to ...
HSBC analysts on Wednesday downgraded AMD (NASDAQ:AMD) stock to Reduce from Buy, and nearly halved their price target to $110 ...